We found that TRIM21 expression levels are potentially elevated in a wide spectrum of tumors (Supplementary Figure S1), including glioma, melanoma, pancreatic adenocarcinoma, testicular germ cell tumors, acute myeloid leukemia, cholangio carcinoma and colorectum adenocarcinoma. Here, TRIM21 is linked to glioma.